Skip to main content
editorial
. 2020 Apr 30;6(2):52–60. doi: 10.1016/S2055-6640(20)30017-0

Table 3.

Safety data related to hepatic, renal or cardiovascular adverse effects of nitazoxanide, where reported across the nine included studies

graphic file with name jve-6-52-g503.jpg

LFTs: liver function tests; NTZ: nitazoxanide; Hepatic: LFT or other relevant biochemical abnormality; Renal: any urinary or renal-related biochemical abnormality (creatinine, urea, electrolytes etc); Cardiovascular: (B-type natriuretic peptide, troponin, chest pain, QT prolongation, cardiac events etc).